Your session is about to expire
← Back to Search
Universal Gloving for C. Difficile Infection (GLORI Trial)
N/A
Waitlist Available
Led By Nasia Safdar, MD PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will compare the effectiveness of universal gloving practices to the standard of care in order to determine if the former can help prevent healthcare-associated Clostridium difficile infections.
Who is the study for?
This trial is for adult patients and healthcare workers in certain VA hospital units, including acute medical or surgical wards. Units must be able to collect data and have support from hospital leadership. It's not for those in long-term care, mixed-acuity, intensive care, or specialty units.
What is being tested?
The study tests if wearing gloves all the time (universal gloving) by healthcare workers can prevent the spread of C. difficile better than just using gloves with known infected patients (standard practice).
What are the potential side effects?
While there are no direct side effects mentioned for participants, universal gloving may impact hand hygiene practices and could potentially lead to increased glove-related skin irritation among healthcare workers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
C. difficile acquisition rates
Secondary study objectives
30-day mortality rate
CAUTI (HAI) rates
CLABSI (HAI) rates
+7 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Enact universal gloving practices
Group II: ControlActive Control1 Intervention
Continue standard of care gloving practices
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,668 Previous Clinical Trials
3,765,856 Total Patients Enrolled
University of Wisconsin, MadisonOTHER
1,237 Previous Clinical Trials
3,200,969 Total Patients Enrolled
2 Trials studying Clostridium Difficile
11,033 Patients Enrolled for Clostridium Difficile
Nasia Safdar, MD PhDPrincipal InvestigatorWilliam S. Middleton Memorial Veterans Hospital, Madison, WI
5 Previous Clinical Trials
11,242 Total Patients Enrolled
1 Trials studying Clostridium Difficile
11,000 Patients Enrolled for Clostridium Difficile
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- The clinical trial is only open to individuals who are being treated in specific medical departments or units.I am currently in or require an intensive care unit.The hospital where you are receiving treatment has a certain number of C. difficile cases to allow for accurate comparison with other hospitals.I am 18 years old or older.I am currently in a hospital ward for patients who have had surgery.I am currently living in a long-term care facility.
Research Study Groups:
This trial has the following groups:- Group 1: Control
- Group 2: Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.